Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.43 |
| ▸ | TDO2 | P48775 | 5/20 | 0.41 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | CD38 | P28907 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19739012 | 0.86 | PRKCQ (0.55) | MAPTALDH1A1MAPK1PRKCQL3MBTL1 | |
| SCHEMBL19738999 | 0.80 | ALDH1A1 (0.51) | MAPTALDH1A1L3MBTL1METCYP3A4 | |
| SCHEMBL19739003 | 0.79 | PIK3CD (0.49) | MAPTALDH1A1MAPK1PRKCQTDO2 | |
| SCHEMBL21291732 | 0.76 | PRKCQ (0.52) | MAPTALDH1A1MAPK1PRKCQTDO2 | |
| SCHEMBL18918978 | 0.74 | MAPT (0.44) | MAPTALDH1A1MAPK1PRKCQTDO2 | |
| SCHEMBL15742447 | 0.74 | TDO2 (0.44) | MAPTALDH1A1MAPK1PRKCQTDO2 | |
| SCHEMBL15740633 | 0.74 | MAPT (0.53) | MAPTALDH1A1PRKCQL3MBTL1MEN1 | |
| SCHEMBL20529665 | 0.73 | MAPT (0.43) | MAPTALDH1A1MAPK1TDO2IDO1 | |
| SCHEMBL16793163 | 0.73 | PRKCQ (0.55) | MAPTALDH1A1MAPK1PRKCQTDO2 | |
| SCHEMBL3449318 | 0.71 | PGK1 (0.48) | MAPTALDH1A1MAPK1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263804-A1 | AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-29 | — | — | US | disclosed |
| WO-2017216293-A1 | AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263804-A1 | AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS | PIK3CD, PIK3CB, PIK3CA | MAPT 4093/4885ALDH1A1 1422/4885MAPK1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.